Novo Nordisk’s CSO Mads Krogsgaard has addressed in a long interview the overall state of the pharma sector. The Danish manager has voiced his skepticism about the market’s increasing interest in the NASH (Non-Alcoholic Steatohepatitis) business, that he deems unjustified, especially as no diagnostic tools alternative to liver biopsy are currently available. Additionally, Thomsen has said himself surprised by the slow spread of PCSK9 inhibitors, such as Repatha (evolocumab) and positively impressed by the approval of Novartis’ and Kite Pharma’s CAR-T therapies. As for Novo Nordisk, Thomas has said he is satisfied of the approvals of factor IX in hemophilia B, of ultra-fast acting insulin Fiasp and of new therapeutic indications for Victoza (liraglutide). Also the approval of Victoza in China has been pivotal for Novo. The drug is the first ever GLP-1 to obtain reimbursement in the country. Novo Nordisk’s CSO has reiterated his high expectations about semaglutide for the treatment of obesity, for which the Denmark-based group is planning an important Phase III clinical trial.